You are here

HOCK LOCK SIEW

Covid-19 exposes SGX's lack of biopharmaceutical issuers

Many of the homegrown players that need to raise funds are still early-stage companies and are not mature enough for the IPO market

nz_sgx_010728.jpg
Singapore-based biotech Cennerv Pharmaceuticals tried twice to list on the Singapore Exchange (SGX) but was forced to withdraw its initial public offer (IPO) due to weak demand.

SINGAPORE-BASED biotech Cennerv Pharmaceuticals tried twice to list on the Singapore Exchange (SGX) but was forced to withdraw its initial public offer (IPO) due to weak demand.

At that time, a clearly disappointed chief executive officer Anil Ratty told shareholders in a statement:"The...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes